|
|
|
NCI DCP News Summary
NCI Funds 32 Grants to Continue Early Detection Research Network's Ground-Breaking Program of Biomarker Discovery and Validation
August 30, 2010
The NCI's Early Detection Research Network (EDRN) awarded 32 new five-year grants to researchers across the country for the discovery and validation of biological markers that signal the earliest stages of cancer. The awards fund:
- 20 Biomarker Developmental Laboratories responsible for development and characterization of new biomarkers or refinement of existing biomarkers;
- 8 Clinical Validation Centers which conduct clinical research on the validation of biomarkers in early cancer detection and risk assessment, and serve as resource centers by participating in collaborative biomarker validation studies;
- 3 Biomarker Reference Laboratories that serve as a resource for clinical and laboratory validation of biomarkers; and a
- Data Coordinating Management and Center which supports statistical and computational analyses, informatics infrastructure, and the coordination of network-wide meetings and conferences.
EDRN also has four collaborative groups that bring together scientists working on related organ sites:
The Breast and Gynecologic Cancer Collaborative Group is chaired by Steven J. Skates, PhD, of Massachusetts General Hospital and Karen Anderson, MD, PhD, of Dana-Farber Cancer Institute.
The Colorectal and Other Gastrointestinal Cancers Collaborative Group is chaired by M. Anthony Hollingsworth, PhD, of the University of Nebraska Medical Center and Dean Brenner, MD, of the University of Michigan.
The Lung and Upper Aerodigestive Cancers Collaborative Group is chaired by Harvey Pass, MD, of New York University School of Medicine, and Pierre Massion, MD, of Vanderbilt University Medical Center, and
The Prostate and Other Urologic Cancers Collaborative Group is chaired by Mark Rubin, MD, Weill Medical College, and James Brooks, MD, of Stanford University.
While current EDRN grants focus efforts on breast, colon, lung, pancreas, prostate, and ovarian cancers, through the EDRN Associate Member program and these Collaborative Groups, investigators researching any type of cancer may propose studies.
The new Network also elected Ian Thompson, MD, of the University of Texas Health Science Center as chair and Joshua LaBaer, MD, PhD, of Arizona State University as co-chair.
Since its creation in 2000, EDRN has progressed from a ground-breaking concept to an operational success, developing more than 127 biomarkers; launching 5 validation studies and completing three; and preparing markers for prevalidation and validation studies. More than 600 publications, 28 patents, and 14 licenses have been generated by research from EDRN scientists. EDRN established clear milestones for reaching 'go' or 'no-go' decisions during the biomarker development process. Based on statistical criteria, performance characteristics of biomarkers, and anticipated clinical use, more than 100 biomarkers have been stopped from further development due to their lack of performance.
Biomarker Developmental Laboratories (Funded under RFA CA-09-017) |
Principal Investigator Institution |
Grant Title Cancer Type Studied |
Carlo Croce, MD
Ohio State University |
MicroRNAs and Ultra Conserved non-coding RNAs: Biomarkers for Cancer Risk, Tumor Detection, Progression and Treatment
Epithelial cancers: lung, breast, prostate, colon |
Hemant Roy, MD
Evanston Northwestern Healthcare Research Institute
Vadim Backman, PhD
Northwestern University |
Spectral Markers for Early Detection of Colon Neoplasia
Colon |
Paul Lampe, PhD
Samir Hanash, PhD
Fred Hutchinson Cancer Research Center |
Affinity-based Strategies to Fast Track Development of Colon Cancer Biomarkers
Colon |
Robert Getzenberg, PhD
Johns Hopkins University
Robert Schoen, MD, MPH
University of Pittsburgh |
Refinement and Discovery of Nuclear Matrix Protein Markers for Colorectal Cancer
Colon and rectum |
William Grady, MD
Fred Hutchinson Cancer Research Center
Sanford Markowitz, MD, PhD
Case Western Reserve University |
Identify and Validate Novel Epigenetic Molecular Markers for Colorectal Neoplasm
Colon and rectum |
Daniel Liebler, PhD
David Taab, PhD
Vanderbilt University Medical Center |
Vanderbilt Biomarker Developmental Laboratory
Colon, rectum, and lung cancer |
Steven Dubinett, MD
David Elashoff, PhD
University of California, Los Angeles
Avrum Spira, MD
Mark Lenburg, PhD
Boston University |
The UCLA-Boston University Lung Cancer Biomarker Development Laboratory.
Lung |
David Sidransky, MD
Johns Hopkins University |
Integrated Development of Novel Molecular Markers
Lung |
Harvey Pass, MD
Margaret Huflejt, PhD
New York University School of Medicine |
The North American Mesothelioma Consortium
Mesothelioma |
Sanjiv Gambhir, MD, PhD
James Brooks, MD
Stanford University |
New Tools for Prostate Cancer Detection and Prognostication.
Prostate |
Arul Chinnaiyan, MD, PhD
University of Michigan
Mark Rubin, MD
Weill Medical College |
A Systems Biology Approach to the Development of Cancer Biomarkers: Extending work on TMPRSS2-ETS gene fusions, developing markers of disease aggression via next generation transcriptome sequencing.
Prostate |
Alvin Liu, PhD
University of Washington |
EDRN Biomarker Developmental Lab
Prostate |
Dan Mercola, MD, PhD
University of California, Irvine
Chung Lee, PhD
Northwestern University |
The Prostate Cancer Tumor Microenvironment Exhibits Differentially Expressed Genes
Prostate |
Hui Zhang, PhD
Johns Hopkins University |
Glycoprotein Biomarkers for the Early Detection of Aggressive Prostate Cancer
Prostate |
Brian Haab, PhD
Van Andel Research Institute
Randall Brand, MD
University of Pittsburgh
Peter Allen, MD
Memorial Sloan-Kettering Cancer Center |
Detection of Pre-invasive Pancreatic Cysts using Protein and Glycan Biomarkers.
Pancreas |
M. Anthony Hollingsworth, PhD
Surinder Batra, PhD
University of Nebraska Medical Center |
Early Diagnosis of Pancreatic Cancer
Pancreas |
Ann Killary, PhD
Subrata Sen, PhD
Marsha Frazier, PhD
The University of Texas M. D. Anderson Cancer Center |
Biomarkers for the Early Detection of Pancreatic Cancer
Pancreas |
Joshua LaBaer, MD, PhD
Arizona State University
Karen Anderson, MD, PhD
Dana-Farber Cancer Institute |
Biomarker Detection using NAPPA Tumor Antigen Arrays
Breast |
Steven J. Skates, PhD
Michael Birrer, MD,PhD
Massachusetts General Hospital
Rony Darpkin, MD, PhD
Dana-Farber Cancer Institute
Steven Carr, PhD
Broad Institute |
Proteomic, Genomic, and Longitudinal Pathways to Ovarian Cancer Biomarker Discovery
Ovary |
Eleftherios Diamandis MD, PhD
Mount Sinai Hospital
(Toronto, Canada) |
An Integrated Systems Biology Approach for Ovarian Cancer Biomarker Discovery.
Ovary |
Back to top
Clinical Validation Centers (Funded under RFA CA-09-018) |
Principal Investigator Institution |
Grant Title Organ Site Focus |
Dean Brenner, MD
University of Michigan |
Great Lakes/New England Clinical Epidemiology and Validation
Esophagus, colon, other gastrointestinal markers |
Paul Engstrom, MD
Fox Chase Cancer Center |
Fox Chase Clinical Epidemiology and Validation Center
Breast, ovary |
Christopher Li, MD, PhD, MPH
Fred Hutchison Cancer Research Center |
Breast and Ovary Cancer Clinical Validation Center
Breast, ovary |
Jeffrey Marks, PhD
Duke University |
Atlantic Breast and Gynecologic Clinical Validation Center
Breast, ovary, uterine cervix |
Pierre Massion, MD
Vanderbilt University Medical Center |
Validation of Biomarkers of Risk for the Early Detection of Lung Cancer
Lung |
William Rom, MD, MPH
New York University School of Medicine |
New York University Lung Cancer Biomarker Center
Lung |
Martin Sanda, MD
|
Beth Israel Deaconess Medical Center |
Harvard/Michigan/Cornell Prostate Cancer Biomarker Clinical Validation Center
Prostate |
Ian Thompson, MD
The University of Texas Health Science Center, San Antonio |
San Antonio Center of Biomarkers of Risk for Prostate Cancer
Prostate |
Back to top
Biomarker Reference Laboratories (Funded under RFA CA-09-019) |
Principal Investigator Institution |
Grant Title |
Daniel Chan, PhD
Johns Hopkins University |
Clinical and Analytical Validation of Cancer Biomarkers |
David Chia, PhD
University of California, Los Angeles |
The Early Detection Research Network Biomarker Resource Laboratory at UCLA |
Sanford Sass, MD
University of Maryland, Baltimore |
University of Maryland, Baltimore Biomarker Reference Laboratory |
Back to top
Data Management and Coordinating Center (Funded under RFA CA-09-020) |
Principal Investigator Institution |
Grant Title |
Ziding Feng, PhD
Fred Hutchinson Cancer Research Center |
Early Detection Research Network: Data Management and Coordinating Center |
Back to top
|
|